Dr. Viprakasit on the Results of the BELIEVE Trial With Luspatercept in Beta-Thalassemia

Video

Vip Viprakasit, MD, DPhil, professor of Pediatrics, and director, Thalassemia Research, Siriraj-Thalassemia Center, Siriaj Hospital, discusses the results of the multicenter BELIEVE trial with luspatercept (Reblozyl) in adult patients with β-thalassemia.

Vip Viprakasit, MD, DPhil, professor of Pediatrics, and director, Thalassemia Research, Siriraj-Thalassemia Center, Siriaj Hospital, discusses the results of the multicenter BELIEVE trial with luspatercept (Reblozyl) in adult patients with β-thalassemia.

Investigators accrued 336 patients from 65 sites across 17 countries to the trial, says Viprakasit. In the phase III BELIEVE trial, investigators evaluated luspatercept versus placebo in patients with β-thalassemia who required regular red blood cell (RBC) transfusions. The primary end point of the trial was ≥33% reduction of RBC transfusion burden from baseline between weeks 13-24 versus the 12 weeks prior to randomization.

The results showed that the primary end point was met in 76.3% of patients in the luspatercept arm versus 34.8% in the placebo arm (P <.0001). After the 24-week period, 45.1% of patients in the luspatercept arm continued to experience the reduction of RBC transfusion burden versus 2.7% of patients in the placebo arm (P <.0001), showing that responses were durable, concludes Viprakasit.

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD